Philippe Chanson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/46280/publications.pdf

Version: 2024-02-01

280 papers	19,683 citations	6592 79 h-index	14702 127 g-index
298 all docs	298 docs citations	298 times ranked	11844 citing authors

#	Article	IF	Citations
1	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. Pituitary, 2022, 25, 64-73.	1.6	7
2	Treatment of acromegaly has substantial effects on body composition: a long-term follow-up study. European Journal of Endocrinology, 2022, 186, 173-181.	1.9	10
3	Reproductive Phenotypes in Men With Acquired or Congenital Hypogonadotropic Hypogonadism: A Comparative Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2812-e2824.	1.8	6
4	Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe. European Journal of Endocrinology, 2022, 186, K17-K24.	1.9	7
5	Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome. Annales D'Endocrinologie, 2022, 83, 119-141.	0.6	23
6	Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3313-e3320.	1.8	7
7	Second brain tumours after pituitary irradiation: lower risk than once thought. Lancet Diabetes and Endocrinology,the, 2022, 10, 552-554.	5.5	0
8	IGF-I Variability Over Repeated Measures in Patients With Acromegaly Under Long-Acting Somatostatin Receptor Ligands. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3644-e3653.	1.8	5
9	Prolactin immunoassay: does the high-dose hook effect still exist?. Pituitary, 2022, 25, 653-657.	1.6	10
10	The heart in growth hormone (GH) deficiency and the cardiovascular effects of GH. Annales D'Endocrinologie, 2021, 82, 210-213.	0.6	6
11	Cardiovascular complications of acromegaly. Annales D'Endocrinologie, 2021, 82, 206-209.	0.6	11
12	Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. Endocrine, 2021, 71, 158-167.	1.1	8
13	McCune-Albright Syndrome in Clinical Practice. Endocrinology, 2021, , 377-386.	0.1	0
14	Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. Endocrine Connections, 2021, 10, 76-83.	0.8	12
15	Endocrinological diagnosis and treatment of TSH-secreting pituitary adenomas. , 2021, , 245-260.		1
16	Clinical aspects of multiple endocrine neoplasia type 1. Nature Reviews Endocrinology, 2021, 17, 207-224.	4.3	64
17	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.1	31
18	Outcome of pituitary hormone deficits after surgical treatment of nonfunctioning pituitary macroadenomas. Endocrine, 2021, 73, 166-176.	1.1	9

#	Article	IF	Citations
19	Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective caseâ€“control study. Journal of Psychiatry and Neuroscience, 2021, 46, E358-E368.	1.4	21
20	Diabetes Increases Severe COVID-19 Outcomes Primarily in Younger Adults. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3364-e3368.	1.8	16
21	International Multicenter Validation Study of the SAGITÂ® Instrument in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3555-3568.	1.8	8
22	Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature. European Journal of Endocrinology, 2021, 185, 99-108.	1.9	8
23	Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312) Tj ETQq1 1 0.784314 rgBT /O	0.6	6
24	Response to Letter to the Editor from Woolcott and Castilla-BancayÃ¡n: â€œDiabetes Increases Severe COVID-19 Outcomes Primarily in Younger Adultsâ€• Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5277-e5278.	1.8	0
25	Epicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3505-3514.	1.8	4
26	Response to Letter to the Editor from Soghomonian: â€œEpicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndromeâ€• Journal of Clinical Endocrinology and Metabolism, 2021, , .	1.8	0
27	Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays. Endocrine Connections, 2021, 10, 1027-1034.	0.8	9
28	Somatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma. European Journal of Endocrinology, 2021, 184, 1-8.	1.9	13
29	McCune-Albright Syndrome in Clinical Practice. Endocrinology, 2021, , 1-10.	0.1	0
30	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	5.5	315
31	Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study. European Journal of Endocrinology, 2021, 185, 863-873.	1.9	12
32	Cost-Utility of Acromegaly Pharmacological Treatments in a French Context. Frontiers in Endocrinology, 2021, 12, 745843.	1.5	4
33	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2021, 9, 813-824.	5.5	34
34	CLINICALLY NON-FUNCTIONING PITUITARY ADENOMAS. Presse Medicale, 2021, 50, 104086.	0.8	3
35	Recent insights in pituitary diseases.. Presse Medicale, 2021, 50, 104094.	0.8	0
36	Cortisol and Aldosterone Responses to Hypoglycemia and Na Depletion in Women With Non-Classic 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 55-64.	1.8	7

#	Article	IF	Citations
37	Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1. Annals of Surgery, 2020, 272, 1094-1101.	2.1	44
38	GnRH stimulation testing and serum inhibin B in males: insufficient specificity for discriminating between congenital hypogonadotropic hypogonadism from constitutional delay of growth and puberty. Human Reproduction, 2020, 35, 2312-2322.	0.4	13
39	Multidisciplinary management of acromegaly: A consensus. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 667-678.	2.6	183
40	Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 1133-1143.	0.6	4
41	The 2016â€“2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. European Journal of Cancer, 2020, 130, 39-50.	1.3	37
42	Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2964-2974.	1.8	26
43	Non-invasive Diagnostic Strategy in ACTH-dependent Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3273-3284.	1.8	62
44	How can we minimise the use of regular oral corticosteroids in asthma?. European Respiratory Review, 2020, 29, 190085.	3.0	34
45	Pituitary Stalk Enlargement in Adults. Neuroendocrinology, 2020, 110, 809-821.	1.2	3
46	Transsphenoidal resection for pituitary adenoma in elderly versus younger patients: a systematic review and meta-analysis. Acta Neurochirurgica, 2020, 162, 1297-1308.	0.9	5
47	Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 1144-1155.	0.6	4
48	Congenital hypogonadotropic hypogonadism/Kallmann syndrome is associated with statural gain in both men and women: a monocentric study. European Journal of Endocrinology, 2020, 182, 185.	1.9	21
49	Central diabetes insipidus and pituitary stalk thickening in adults: distinction of neoplastic from non-neoplastic lesions. European Journal of Endocrinology, 2020, 183, 95-105.	1.9	9
50	Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma. European Journal of Endocrinology, 2020, 183, 221-231.	1.9	8
51	Pituitary stalk thickening: neoplastic or not? - authorâ€™s response to the letter by Wang et al.. European Journal of Endocrinology, 2020, 183, L23-L25.	1.9	0
52	Hypertension in Acromegaly. Updates in Hypertension and Cardiovascular Protection, 2020, , 167-179.	0.1	0
53	68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5843-5852.	1.8	36
54	Update in pituitary disorders. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101308.	2.2	0

#	Article	IF	Citations
55	The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101290.	2.2	115
56	Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGITÂ® validation study. Pituitary, 2019, 22, 476-487.	1.6	22
57	Other Pituitary Conditions and Pregnancy. Endocrinology and Metabolism Clinics of North America, 2019, 48, 583-603.	1.2	7
58	An update on clinical care for pregnant women with acromegaly. Expert Review of Endocrinology and Metabolism, 2019, 14, 85-96.	1.2	21
59	Growth Hormone Response to Oral Glucose Load: From Normal to Pathological Conditions. Neuroendocrinology, 2019, 108, 244-255.	1.2	34
60	Contribution of functionally assessed GHRHR mutations to idiopathic isolated growth hormone deficiency in patients without GH1 mutations. Human Mutation, 2019, 40, 2033-2043.	1.1	9
61	Prolactin Assays and Regulation of Secretion: Animal and Human Data. Contemporary Endocrinology, 2019, , 55-78.	0.3	3
62	Acromegaly. Nature Reviews Disease Primers, 2019, 5, 20.	18.1	247
63	National acromegaly registries. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101264.	2.2	65
64	Hypermethylator Phenotype and Ectopic GIP Receptor in GNAS Mutation-Negative Somatotropinomas. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1777-1787.	1.8	25
65	Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the BicÃªtre cohort, and review of the literature. Endocrine, 2019, 63, 348-360.	1.1	24
66	Signs and symptoms of acromegaly at diagnosis: the physicianâ€™s and the patientâ€™s perspectives in the ACRO-POLIS study. Endocrine, 2019, 63, 120-129.	1.1	51
67	Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas. European Journal of Endocrinology, 2019, 181, D1-D13.	1.9	24
68	MON-244 GnRH Test Does Not Efficiently Discriminate Congenital Isolated Hypogonadotropic Hypogonadism from Constitutional Delay of Growth and Puberty in Males. Journal of the Endocrine Society, 2019, 3, .	0.1	0
69	Genomic Alterations and Complex Subclonal Architecture in Sporadic GH-Secreting Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1929-1939.	1.8	43
70	Physiopathology, Diagnosis, and Treatment of Nonfunctioning Pituitary Adenomas. Endocrinology, 2018, , 93-128.	0.1	1
71	Worse Healthâ€Related Quality of Life at longâ€term followâ€up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the <scp>ERCUSYN</scp>. Clinical Endocrinology, 2018, 88, 787-798.	1.2	40
72	Preoperative medical treatment in Cushingâ€™s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. European Journal of Endocrinology, 2018, 178, 399-409.	1.9	37

#	Article	IF	Citations
73	MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1027-1032.	3.3	88
74	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	1.9	196
75	Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability. Frontiers in Endocrinology, 2018, 9, 706.	1.5	40
76	A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. European Journal of Endocrinology, 2018, 179, 97-108.	1.9	27
77	Screening of acromegaly in adults with obstructive sleep apnea: is it worthwhile?. Endocrine, 2018, 61, 4-6.	1.1	13
78	A Consensus Statement on acromegaly therapeutic outcomes. Nature Reviews Endocrinology, 2018, 14, 552-561.	4.3	382
79	Macimorelin as a Diagnostic Test for Adult GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3083-3093.	1.8	71
80	Physiopathology, Diagnosis, and Treatment of Nonfunctioning Pituitary Adenomas. Endocrinology, 2018, , 1-37.	0.1	0
81	Therapy for Acromegaly. , 2018, , 230-247.		0
82	Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. European Journal of Endocrinology, 2017, 176, 645-655.	1.9	133
83	Anti-MÃ¼llerian Hormone and Ovarian Morphology in Women With Isolated Hypogonadotropic Hypogonadism/Kallmann Syndrome: Effects of Recombinant Human FSH. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1102-1111.	1.8	55
84	Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. European Journal of Endocrinology, 2017, 176, 769-777.	1.9	107
85	Prolactinoma. , 2017, , 467-514.		14
86	Classification of Patients With GH Disorders May Vary According to the IGF-I Assay. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2844-2852.	1.8	28
87	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. European Journal of Endocrinology, 2017, 176, 613-624.	1.9	42
88	Cabergoline in acromegaly. Pituitary, 2017, 20, 121-128.	1.6	48
89	Acromegaly at diagnosis in 3173 patients from the LiÃ¨ge Acromegaly Survey (LAS) Database. Endocrine-Related Cancer, 2017, 24, 505-518.	1.6	164
90	Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas. Journal of the Endocrine Society, 2017, 1, 221-230.	0.1	25

#	Article	IF	Citations
91	Group 2: Adrenal insufficiency: screening methods and confirmation of diagnosis. Annales D'Endocrinologie, 2017, 78, 495-511.	0.6	20
92	Group 5: Acute adrenal insufficiency in adults and pediatric patients. Annales D'Endocrinologie, 2017, 78, 535-543.	0.6	17
93	In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism. European Journal of Endocrinology, 2017, 177, 257-266.	1.9	12
94	Effects of cortisol on the heart: characterization of myocardial involvement in cushing's disease by longitudinal cardiac MRI T1 mapping. Journal of Magnetic Resonance Imaging, 2017, 45, 147-156.	1.9	14
95	Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. European Journal of Endocrinology, 2017, 176, 213-220.	1.9	21
96	Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea. Journal of the Endocrine Society, 2017, 1, 1362-1371.	0.1	38
97	Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data. Drug Design, Development and Therapy, 2017, Volume 11, 1489-1495.	2.0	12
98	Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushingâ€™s syndrome. JCI Insight, 2017, 2, .	2.3	38
99	AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells. Endocrine-Related Cancer, 2016, 23, 433-443.	1.6	24
100	Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3450-3458.	1.8	118
101	Prevalence ofKISS1 Receptormutations in a series of 603 patients with normosmic congenital hypogonadotrophic hypogonadism and characterization of novel mutations: a single-centre study. Human Reproduction, 2016, 31, 1363-1374.	0.4	47
102	Diabetes insipidus and pregnancy. Annales D'Endocrinologie, 2016, 77, 135-138.	0.6	24
103	Germline Prolactin Receptor Mutation Is Not a Major Cause of Sporadic Prolactinoma in Humans. Neuroendocrinology, 2016, 103, 738-745.	1.2	17
104	Mild pituitary phenotype in 3- and 12-month-old Aip-deficient male mice. Journal of Endocrinology, 2016, 231, 59-69.	1.2	15
105	Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary SjÃ¶gren syndrome: comparison of different kits. Annals of the Rheumatic Diseases, 2016, 75, 633-635.	0.5	19
106	Very low frequency of germline GPR101 genetic variation and no biallelic defects with AIP in a large cohort of patients with sporadic pituitary adenomas. European Journal of Endocrinology, 2016, 174, 523-530.	1.9	44
107	SAGITÂ®: clinician-reported outcome instrument for managing acromegaly in clinical practiceâ€”development and results from a pilot study. Pituitary, 2016, 19, 39-49.	1.6	56
108	Serum PTH reference values established by an automated third-generation assay in vitamin D-replete subjects with normal renal function: consequences of diagnosing primary hyperparathyroidism and the classification of dialysis patients. European Journal of Endocrinology, 2016, 174, 315-323.	1.9	29

#	Article	IF	Citations
109	Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs. Neuroendocrinology, 2016, 103, 50-58.	1.2	31
110	Diagnosis of acromegaly: black, whiteâ€¦ and sometimes gray!. Archives of Endocrinology and Metabolism, 2016, 60, 505-506.	0.3	2
111	Fractionated stereotactic radiotherapy: an interesting alternative to stereotactic radiosurgery in acromegaly. Endocrine, 2015, 50, 529-530.	1.1	2
112	New insights in prolactin: pathological implications. Nature Reviews Endocrinology, 2015, 11, 265-275.	4.3	178
113	Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY. Annales D'Endocrinologie, 2015, 76, 664-670.	0.6	22
114	Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'Ã©tude des Tumeurs Endocrines (GTE) retrospective study. European Journal of Endocrinology, 2015, 172, 309-319.	1.9	44
115	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. European Journal of Endocrinology, 2015, 172, R227-R239.	1.9	114
116	Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocrine-Related Cancer, 2015, 22, 169-177.	1.6	78
117	Management of nonfunctioning pituitary incidentaloma. Annales D'Endocrinologie, 2015, 76, 191-200.	0.6	48
118	Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocrine-Related Cancer, 2015, 22, 745-757.	1.6	155
119	Management of clinically non-functioning pituitary adenoma. Annales D'Endocrinologie, 2015, 76, 239-247.	0.6	136
120	Macroprolactinomas in Children and Adolescents: Factors Associated With the Response to Treatment in 77 Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1177-1186.	1.8	83
121	Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. European Journal of Endocrinology, 2015, 172, 473-481.	1.9	84
122	Ovarian macrocysts and gonadotropeâ€“ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease. European Journal of Endocrinology, 2015, 172, 141-149.	1.9	19
123	Post-surgical management of non-functioning pituitary adenoma. Annales D'Endocrinologie, 2015, 76, 228-238.	0.6	65
124	Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. European Journal of Endocrinology, 2015, 173, 693-702.	1.9	44
125	Pituitary Apoplexy. Endocrine Reviews, 2015, 36, 622-645.	8.9	270
126	Pituitary Apoplexy. Endocrinology and Metabolism Clinics of North America, 2015, 44, 199-209.	1.2	46

#	Article	IF	Citations
127	Genetic mutations in sporadic pituitary adenomasâ€"what to screen for?. Nature Reviews Endocrinology, 2015, 11, 43-54.	4.3	86
128	Cardiac Structure and Function in Cushing's Syndrome: A Cardiac Magnetic Resonance Imaging Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2144-E2153.	1.8	65
129	Hepatobiliary and Pancreatic Neoplasms in Patients With McCune-Albright Syndrome. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E97-E101.	1.8	75
130	Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation. New England Journal of Medicine, 2014, 371, 2363-2374.	13.9	292
131	Lessons From McCune-Albright Syndromeâ€"Associated Intraductal Papillary Mucinous Neoplasms. JAMA Surgery, 2014, 149, 858.	2.2	33
132	Expert consensus document: A consensus on the medical treatment of acromegaly. Nature Reviews Endocrinology, 2014, 10, 243-248.	4.3	306
133	Insulin-like Peptide 3 (INSL3) in Men With Congenital Hypogonadotropic Hypogonadism/Kallmann Syndrome and Effects of Different Modalities of Hormonal Treatment: A Single-Center Study of 281 Patients. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E268-E275.	1.8	46
134	Ketoconazole in Cushing's Disease: Is It Worth a Try?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1623-1630.	1.8	231
135	Growth Hormone, Insulin-Like Growth Factor-1, and the Kidney: Pathophysiological and Clinical Implications. Endocrine Reviews, 2014, 35, 234-281.	8.9	171
136	Acromegaly. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 124, 197-219.	1.0	40
137	Impact of Successful Treatment of Acromegaly on Overnight Heart Rate Variability and Sleep Apnea. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2925-2931.	1.8	46
138	Acromegaly and McCune-Albright Syndrome. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1955-1969.	1.8	149
139	Hepato-pancreato-biliary lesions are present in both Carney complex and McCune Albright syndrome. Molecular and Cellular Endocrinology, 2014, 382, 344-345.	1.6	8
140	Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary, 2014, 17, 81-89.	1.6	122
141	Management of hyperglycaemia in Cushing's disease: Expertsâ€™ proposals on the use of pasireotide. Diabetes and Metabolism, 2013, 39, 34-41.	1.4	54
142	Frequent Large GermlineHRPT2Deletions in a French National Cohort of Patients With Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E403-E408.	1.8	107
143	Computed Tomography of the Anterior Skull Base in Kallmann Syndrome Reveals Specific Ethmoid Bone Abnormalities Associated With Olfactory Bulb Defects. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E537-E546.	1.8	31
144	Primary hyperparathyroidism in pregnancy. Endocrine, 2013, 44, 591-597.	1.1	65

#	Article	IF	Citations
145	Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe dâ€™Ã©tude des Tumeurs Endocrines (GTE) cohort study. Human Molecular Genetics, 2013, 22, 1940-1948.	1.4	81
146	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology, 2012, 167, 651-662.	1.9	173
147	Cardiovascular findings and management in Turner syndrome: insights from a French cohort. European Journal of Endocrinology, 2012, 167, 517-522.	1.9	39
148	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	3.2	277
149	Pathophysiology of Renal Calcium Handling in Acromegaly: What Lies behind Hypercalciuria?. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2124-2133.	1.8	48
150	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology, 2012, 167, 887-887.	1.9	2
151	No Evidence of a Detrimental Effect of Cabergoline Therapy on Cardiac Valves in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1714-E1719.	1.8	57
152	High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. European Journal of Endocrinology, 2012, 166, 261-268.	1.9	50
153	Germline AIP Mutations in Apparently Sporadic Pituitary Adenomas: Prevalence in a Prospective Single-Center Cohort of 443 Patients. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E663-E670.	1.8	157
154	Growth hormone effects on cortical bone dimensions in young adults with childhood-onset growth hormone deficiency. Osteoporosis International, 2012, 23, 2219-2226.	1.3	23
155	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. Journal of Hepatology, 2012, 56, 184-191.	1.8	354
156	Clinical Characteristics and Outcome of Acromegaly Induced by Ectopic Secretion of Growth Hormone-Releasing Hormone (GHRH): A French Nationwide Series of 21 Cases. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2093-2104.	1.8	81
157	Treatment of neurogenic diabetes insipidus. Annales D'Endocrinologie, 2011, 72, 496-499.	0.6	21
158	Mitotane, Metyrapone, and Ketoconazole Combination Therapy as an Alternative to Rescue Adrenalectomy for Severe ACTH-Dependent Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2796-2804.	1.8	187
159	Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects ofÂdifferent modalities of hormonal treatment. Fertility and Sterility, 2011, 95, 2324-2329.e3.	0.5	30
160	Integrated Genomic Profiling Identifies Loss of Chromosome 11p Impacting Transcriptomic Activity in Aggressive Pituitary PRL Tumors. Brain Pathology, 2011, 21, 533-543.	2.1	46
161	Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. European Journal of Endocrinology, 2011, 164, 877-884.	1.9	140
162	Current management practices for acromegaly: an international survey. Pituitary, 2011, 14, 125-133.	1.6	89

#	Article	IF	Citations
163	Body Fluid Expansion in Acromegaly Is Related to Enhanced Epithelial Sodium Channel (ENaC) Activity. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2127-2135.	1.8	49
164	AIPMutation in Pituitary Adenomas. New England Journal of Medicine, 2011, 364, 1973-1975.	13.9	27
165	RecurrentPRKAR1AMutation in Acrodysostosis with Hormone Resistance. New England Journal of Medicine, 2011, 364, 2218-2226.	13.9	162
166	Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2741-2749.	1.8	54
167	Prevalence and Incidence of Diabetes Mellitus in Adult Patients on Growth Hormone Replacement for Growth Hormone Deficiency: A Surveillance Database Analysis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2255-2261.	1.8	60
168	The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. European Journal of Endocrinology, 2011, 165, 383-392.	1.9	322
169	Place of Cabergoline in Acromegaly: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1327-1335.	1.8	255
170	Normosmic Congenital Hypogonadotropic Hypogonadism Due to TAC3/TACR3 Mutations: Characterization of Neuroendocrine Phenotypes and Novel Mutations. PLoS ONE, 2011, 6, e25614.	1.1	83
171	Endocrine Aspects of Obstructive Sleep Apnea. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 483-495.	1.8	202
172	Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocrine-Related Cancer, 2010, 17, 797-807.	1.6	52
173	Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E373-E383.	1.8	323
174	A new FSHÎ² mutation in a 29-year-old woman with primary amenorrhea and isolated FSH deficiency: functional characterization and ovarian response to human recombinant FSH. European Journal of Endocrinology, 2010, 162, 633-641.	1.9	50
175	A Consensus on Criteria for Cure of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3141-3148.	1.8	697
176	Non-syndromic congenital hypogonadotropic hypogonadism: clinical presentation and genotypeâ€“phenotype relationships. European Journal of Endocrinology, 2010, 162, 835-851.	1.9	104
177	Acromegaly and Pregnancy: A Retrospective Multicenter Study of 59 Pregnancies in 46 Women. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4680-4687.	1.8	111
178	Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. European Journal of Endocrinology, 2010, 163, 193-200.	1.9	167
179	TAC3andTACR3Defects Cause Hypothalamic Congenital Hypogonadotropic Hypogonadism in Humans. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2287-2295.	1.8	214
180	Metabolic Syndrome in Cushingâ€™s Syndrome. Neuroendocrinology, 2010, 92, 96-101.	1.2	99

#	Article	IF	Citations
181	Prevalence of Metabolic Syndrome in Adult Hypopituitary Growth Hormone (GH)-Deficient Patients Before and After GH Replacement. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 74-81.	1.8	113
182	Congenital hypogonadotropic hypogonadism in females: Clinical spectrum, evaluation and genetics. Annales D'Endocrinologie, 2010, 71, 158-162.	0.6	34
183	Ovarian dysfunction by activating mutation of GS alpha: McCune-Albright syndrome as a model. Annales D'Endocrinologie, 2010, 71, 210-213.	0.6	12
184	Female Gonadal Function before and after Treatment of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4518-4525.	1.8	77
185	Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4592-4599.	1.8	202
186	Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocrine-Related Cancer, 2010, 17, 361-371.	1.6	81
187	Comparative Validation of the Growth Hormone-Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency Using a Growth Hormone Assay Conforming to Recent International Recommendations. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3684-3692.	1.8	20
188	Surgical Approaches in 84 Patients with Insulinomas in Multiple Endocrine Neoplasia Type 1 (MEN 1).. , 2010, , P2-88-P2-88.		0
189	Efficacy of Cabergoline in the Treatment of Acromegaly: A Meta-Analysis.. , 2010, , P3-268-P3-268.		0
190	Isolated Familial Hypogonadotropic Hypogonadism and aGNRH1Mutation. New England Journal of Medicine, 2009, 360, 2742-2748.	13.9	247
191	Long-Term Results of Stereotactic Radiosurgery in Secretory Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3400-3407.	1.8	164
192	Does attainment of target levels of growth hormone and insulin-like growth factor I improve acromegaly prognosis?. Nature Clinical Practice Endocrinology and Metabolism, 2009, 5, 70-71.	2.9	6
193	Cinacalcet Reduces Serum Calcium Concentrations in Patients with Intractable Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2766-2772.	1.8	134
194	Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1500-1508.	1.8	191
195	D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly. European Journal of Endocrinology, 2009, 161, 231-235.	1.9	32
196	Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors. International Journal of Cancer, 2009, 124, 751-753.	2.3	14
197	Acromegaly. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 555-574.	2.2	133
198	Preface. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, vii-viii.	2.2	1

#	Article	IF	Citations
199	Classification et physiopathologie des adÃ©nomes hypophysaires. Bulletin De L'Academie Nationale De Medecine, 2009, 193, 1543-1556.	0.0	3
200	Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly. Pituitary, 2008, 11, 129-139.	1.6	28
201	Pregnancy outcomes following cabergoline treatment: extended results from a 12â€year observational study. Clinical Endocrinology, 2008, 68, 66-71.	1.2	120
202	Control of IGFâ€I levels with titrated dosing of lanreotide Autogel over 48Âweeks in patients with acromegaly. Clinical Endocrinology, 2008, 69, 299-305.	1.2	70
203	Acromegaly. Orphanet Journal of Rare Diseases, 2008, 3, 17.	1.2	188
204	Primary amenorrhea revealing an occult progesterone-secreting ovarian tumor. Fertility and Sterility, 2008, 90, 1198.e1-1198.e5.	0.5	14
205	Emerging drugs for acromegaly. Expert Opinion on Emerging Drugs, 2008, 13, 273-293.	1.0	15
206	Epithelial Sodium Channel Is a Key Mediator of Growth Hormone-Induced Sodium Retention in Acromegaly. Endocrinology, 2008, 149, 3294-3305.	1.4	86
207	Kallmannâ€™s Syndrome: A Comparison of the Reproductive Phenotypes in Men Carrying KAL1 and FGFR1/KAL2 Mutations. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 758-763.	1.8	109
208	Rapidly Reversible Myocardial Edema in Patients with Acromegaly: Assessment with Ultrafast T2 Mapping in a Single-Breath-Hold MRI Sequence. American Journal of Roentgenology, 2008, 190, 1576-1582.	1.0	40
209	Cardiac Effects of Growth Hormone Treatment in Chronic Heart Failure: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 180-185.	1.8	63
210	Impact of Somatostatin Analogs on the Heart in Acromegaly: A Metaanalysis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1743-1747.	1.8	133
211	Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. European Journal of Endocrinology, 2007, 157, 1-8.	1.9	127
212	Benign cortisol-secreting adrenocortical adenomas produce small amounts of androgens. Clinical Endocrinology, 2007, 66, 778-788.	1.2	19
213	McCune-Albright syndrome in adulthood. Pediatric Endocrinology Reviews, 2007, 4 Suppl 4, 453-62.	1.2	9
214	Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clinical Endocrinology, 2006, 65, 536-543.	1.2	142
215	APRKAR1AMutation Associated with Primary Pigmented Nodular Adrenocortical Disease in 12 Kindreds. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1943-1949.	1.8	116
216	McCune-Albright Syndrome and Acromegaly: Effects of Hypothalamopituitary Radiotherapy and/or Pegvisomant in Somatostatin Analog-Resistant Patients. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4957-4961.	1.8	54

#	Article	IF	Citations
217	Less is more risky? Growth hormone and insulin-like growth factor 1 levels and cardiovascular risk. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 650-651.	2.9	10
218	Testicular Anti-MÃ¼llerian Hormone Secretion Is Stimulated by Recombinant Human FSH in Patients with Congenital Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 724-728.	1.8	122
219	Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. European Journal of Endocrinology, 2005, 152, 61-66.	1.9	148
220	A Critical Analysis of Pituitary Tumor Shrinkage during Primary Medical Therapy in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4405-4410.	1.8	193
221	Type A Insulin Resistance Syndrome Revealing a Novel Lamin A Mutation. Diabetes, 2005, 54, 1873-1878.	0.3	75
222	Outcome of Gamma Knife Radiosurgery in 82 Patients with Acromegaly: Correlation with Initial Hypersecretion. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4483-4488.	1.8	209
223	Comparison of fast Fourier transform and autoregressive spectral analysis for the study of heart rate variability in diabetic patients. International Journal of Cardiology, 2005, 104, 307-313.	0.8	60
224	Primary Amenorrhea Due to Constant High Progesterone Level Revealing a Leydig Cell Ovarian Tumor. Fertility and Sterility, 2005, 84, S161-S162.	0.5	0
225	Impact of Growth Hormone (GH) Treatment on Cardiovascular Risk Factors in GH-Deficient Adults: A Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2192-2199.	1.8	321
226	Long-Term Outcome of Patients with Acromegaly and Congestive Heart Failure. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5308-5313.	1.8	89
227	Parental Origin of GsÎ± Mutations in the McCune-Albright Syndrome and in Isolated Endocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3007-3009.	1.8	61
228	Pituitary Magnetic Resonance Imaging Findings Do Not Influence Surgical Outcome in Adrenocorticotropin-Secreting Microadenomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3371-3376.	1.8	94
229	Management of pituitary apoplexy. Expert Opinion on Pharmacotherapy, 2004, 5, 1287-1298.	0.9	46
230	Chromogranin A as serum marker of pituitary adenomas. Clinical Endocrinology, 2003, 59, 644-648.	1.2	11
231	Hypogonadotropic hypogonadism as a model of post-natal testicular anti-MÃ¼llerian hormone secretion in humans. Molecular and Cellular Endocrinology, 2003, 211, 51-54.	1.6	25
232	Cardiac Effects of Growth Hormone in Adults With Growth Hormone Deficiency. Circulation, 2003, 108, 2648-2652.	1.6	155
233	Pituitary Incidentalomas. , 2003, 13, 124-135.		14
234	Severe hyponatremia as a frequent revealing sign of hypopituitarism after 60 years of age. European Journal of Endocrinology, 2003, 149, 177-178.	1.9	33

#	Article	IF	Citations
235	Normal Pituitary Hypertrophy as a Frequent Cause of Pituitary Incidentaloma: A Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3009-3015.	1.8	101
236	Efficacy of the Long-Acting Octreotide Formulation (Octreotide-Lar) in Patients with Thyrotropin-Secreting Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2849-2853.	1.8	112
237	Impact of Growth Hormone-Lowering Treatments on Heart Function in Acromegaly. Growth Hormone, 2001, , 45-57.	0.2	3
238	Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clinical Endocrinology, 2000, 53, 445-451.	1.2	70
239	Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. Pituitary, 2000, 2, 269-276.	1.6	42
240	Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary, 2000, 3, 193-197.	1.6	24
241	Effects of Human Recombinant Luteinizing Hormone and Follicle-Stimulating Hormone in Patients with Acquired Hypogonadotropic Hypogonadism: Study of Sertoli and Leydig Cell Secretions and Interactions. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3239-3244.	1.8	72
242	Measurement of Plasma Free Luteinizing Hormone Â-Subunit in Women. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2293-2298.	1.8	2
243	The Antigonadotropic Activity of a 19-Nor-Progesterone Derivative Is Exerted Both at the Hypothalamic and Pituitary Levels in Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4191-4196.	1.8	57
244	AntimÃ¼llerian Hormone in Patients with Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2696-2699.	1.8	77
245	Functional hypothalamic amenorrhoea: a partial and reversible gonadotrophin deficiency of nutritional origin. Clinical Endocrinology, 1999, 50, 229-235.	1.2	92
246	Biochemical characterization of a Ca2+/NAD(P)H-dependent H2O2 generator in human thyroid tissue. Biochimie, 1999, 81, 373-380.	1.3	61
247	Antimullerian Hormone in Patients with Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2696-2699.	1.8	64
248	Decreased regional blood flow in patients with acromegaly. Clinical Endocrinology, 1998, 49, 725-731.	1.2	45
249	Germ-Line Mutation Analysis in Patients with Multiple Endocrine Neoplasia Type 1 and Related Disorders. American Journal of Human Genetics, 1998, 63, 455-467.	2.6	197
250	Absence of activating mutations in the GnRH receptor gene in human pituitary gonadotroph adenomas. European Journal of Endocrinology, 1998, 139, 157-160.	1.9	25
251	Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. BMJ: British Medical Journal, 1998, 316, 1132-1133.	2.4	70
252	Pitfall of Petrosal Sinus Sampling in a Cushing's Syndrome Secondary to Ectopic Adrenocorticotropin-Corticotropin Releasing Hormone (ACTH-CRH) Secretion. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 305-308.	1.8	48

#	Article	IF	Citations
253	Panhypopituitarism as a Model to Study the Metabolism of Dehydroepiandrosterone (DHEA) in Humans¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2578-2585.	1.8	116
254	Free Luteinizing-Hormone Beta-Subunit in Normal Subjects and Patients with Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1397-1402.	1.8	25
255	A Family with Hypogonadotropic Hypogonadism and Mutations in the Gonadotropin-Releasing Hormone Receptor. New England Journal of Medicine, 1997, 337, 1597-1603.	13.9	473
256	Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits?. European Journal of Endocrinology, 1997, 136, 359-361.	1.9	10
257	Panhypopituitarism as a Model to Study the Metabolism of Dehydroepiandrosterone (DHEA) in Humans. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2578-2585.	1.8	86
258	The antigonadotropic activity of progestins (19-nortestosterone and 19- norprogesterone derivatives) is not mediated through the androgen receptor. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 4218-4223.	1.8	19
259	Diagnosis of secondary hypoadrenalism. Clinical Endocrinology, 1996, 45, 122-123.	1.2	0
260	Osteoblastic cells derived fronm isolated lesions of fibrous dysplasia contain activating somatic mutatuions of thje Gsî± gene. Human Molecular Genetics, 1995, 4, 1675-1676.	1.4	78
261	Even after priming with ovarian steroids or pulsatile gonadotropin- releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhea. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 2102-2107.	1.8	14
262	Thyrotropin-releasing hormone (TRH) binding sites and thyrotropin response to TRH are regulated by thyroid hormones in human thyrotropic adenomas. European Journal of Endocrinology, 1994, 130, 559-564.	1.9	13
263	The diagnostic value of fine-needle aspiration biopsy under ultrasonography in nonfunctional thyroid nodules: A prospective study comparing cytologic and histologic findings. American Journal of Medicine, 1994, 97, 152-157.	0.6	128
264	McCuneâ€“Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. European Journal of Endocrinology, 1994, 131, 229-234.	1.9	90
265	Inhibin and follicle-stimulating hormone levels in gonadotroph adenomas: evidence of a positive correlation with tumour volume in men. Clinical Endocrinology, 1993, 38, 301-309.	1.2	29
266	Hyperfunctioning unilateral adrenal macronodule in three patients with Cushing's disease: hormonal and imaging characterization. European Journal of Endocrinology, 1993, 129, 284-290.	1.9	10
267	Clinical Pharmacokinetics of Octreotide. Clinical Pharmacokinetics, 1993, 25, 375-391.	1.6	110
268	Non-responsiveness of serum gonadotropins and testosterone to pulsatile GnRH in hemochromatosis suggesting a pituitary defect. European Journal of Endocrinology, 1993, 128, 351-354.	1.9	35
269	Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas: A Follow-up of 52 Patients. Annals of Internal Medicine, 1993, 119, 236.	2.0	189
270	Resistance to Somatostatin (SRIH) Analog Therapy in Acromegaly. Hormone Research, 1992, 38, 94-99.	1.8	16

#	Article	IF	Citations
271	Heart failure and octreotide in acromegaly. Lancet, The, 1992, 339, 242-243.	6.3	5
272	Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995). European Journal of Endocrinology, 1991, 124, 487-491.	1.9	25
273	Cardiovascular Effects of the Somatostatin Analog Octreotide in Acromegaly. Annals of Internal Medicine, 1990, 113, 921.	2.0	125
274	Pituitary granuloma and pyoderma gangrenosum. Journal of Endocrinological Investigation, 1990, 13, 677-681.	1.8	17
275	The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas. Journal of Neurosurgery, 1989, 71, 687-690.	0.9	46
276	TORSADE DE POINTES AND Q-T PROLONGATION IN SECONDARY HYPOTHYROIDISM. Lancet, The, 1988, 332, 170-171.	6.3	7
277	Management of early postoperative diabetes insipidus with parenteral desmopressin. European Journal of Endocrinology, 1988, 117, 513-516.	1.9	10
278	The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.9	36
279	RAPID IMPROVEMENT IN SLEEP APNOEA OF ACROMEGALY AFTER SHORT-TERM TREATMENT WITH SOMATOSTATIN ANALOGUE SMS 201-995. Lancet, The, 1986, 327, 1270-1271.	6.3	43
280	Effects of Human Recombinant Luteinizing Hormone and Follicle-Stimulating Hormone in Patients with Acquired Hypogonadotropic Hypogonadism: Study of Sertoli and Leydig Cell Secretions and Interactions. , 0, .		19